Stocktoria
Prestige Consumer Healthcare Inc. PBH
NYSE · stock · Pharmaceutical Preparations · website · IPO 2005-02-10
Prestige Consumer Healthcare Inc. financials (annual)
Bars are annual figures from 2017 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | $943.4M | $963.0M | $975.8M | $1.0B | $882.1M |
| Gross profit | $595.6M | $634.5M | $624.4M | $625.3M | $620.6M | $547.5M | $552.2M | $555.6M | $576.5M | $500.3M |
| Operating income | $309.4M | $336.8M | $342.4M | -$22.4M | $329.9M | $297.4M | $291.2M | $67.5M | $215.5M | $205.6M |
| Interest expense | — | $1.8M | $5.2M | $4.4M | — | — | — | — | — | — |
| Income tax | $67.2M | $69.6M | $66.7M | -$11.6M | $57.1M | $39.4M | $48.9M | -$2.3M | -$232.5M | $41.5M |
| Net income | $190.3M | $214.6M | $209.3M | -$82.3M | $205.4M | $164.7M | $142.3M | -$35.8M | $339.6M | $69.4M |
| EPS (diluted) | $3.91 | $4.29 | $4.17 | $-1.65 | $4.04 | $3.25 | $2.78 | $-0.69 | $6.34 | $1.30 |
| Operating cash flow | $257.6M | $251.5M | $248.9M | $229.7M | $259.9M | $235.6M | $217.1M | $189.3M | $210.1M | $148.7M |
| Free cash flow | $246.4M | $243.3M | $239.4M | $221.9M | $250.3M | $213.4M | $202.6M | $178.8M | $197.6M | $145.7M |
| Cash & equivalents | $63.9M | $97.9M | $46.5M | $58.5M | $27.2M | $32.3M | $94.8M | $27.5M | $32.5M | $41.9M |
| Inventory | $159.1M | $147.7M | $138.7M | $162.1M | $120.3M | $115.0M | $116.0M | $119.9M | $118.5M | $115.6M |
| Total assets | $3.5B | $3.4B | $3.3B | $3.4B | $3.7B | $3.4B | $3.5B | $3.4B | $3.8B | $3.9B |
| Total liabilities | $1.6B | $1.6B | $1.7B | $1.9B | $2.1B | $2.1B | $2.3B | $2.3B | $2.6B | $3.1B |
| Shareholders' equity | $1.9B | $1.8B | $1.7B | $1.4B | $1.6B | $1.4B | $1.2B | $1.1B | $1.2B | $822.5M |
Growth · year-over-year · Revenue CAGR 2.4%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -4.3% | +1.1% | -0.2% | +3.8% | +15.2% | -2.0% | -1.3% | -6.3% | +18.0% | +9.4% |
| Net income growth | -11.3% | +2.5% | — | -140.1% | +24.7% | +15.7% | — | -110.5% | +389.3% | -30.5% |
| EPS growth | -8.9% | +2.9% | — | -140.8% | +24.3% | +16.9% | — | -110.9% | +387.7% | -30.9% |
| Free cash flow growth | +1.3% | +1.6% | +7.9% | -11.3% | +17.3% | +5.3% | +13.3% | -9.5% | +35.6% | -15.7% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.